Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction - PubMed (original) (raw)
Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction
Zvi Ackerman et al. Hypertension. 2005 May.
Abstract
The most known risk factor for nonalcoholic fatty liver disease (NAFLD) is the metabolic syndrome. In this study, we characterized changes in liver pathology, hepatic lipid composition, and hepatic iron concentration (HIC) occurring in rats given fructose-enriched diet (FED), with and without therapeutic maneuvers to reduce blood pressure and plasma triglycerides. Rats were given FED or standard rat chow for 5 weeks. Rats on FED were divided into 4 groups: receiving amlodipine (15 mg/kg per day), captopril (90 mg/kg per day), bezafibrate (10 mg/kg per day) in the last 2 weeks, or a control group that received FED only. FED rats had hepatic macrovesicular and microvesicular fat deposits develop, with increase in hepatic triglycerides (+198%) and hepatic cholesterol (+89%), but a decrease in hepatic phospholipids (-36%), hypertriglyceridemia (+223%), and hypertension (+15%), without increase in HIC. Amlodipine reduced blood pressure (-18%), plasma triglycerides (-12%), but there was no change in hepatic triglycerides and phospholipids concentrations. Captopril reduced blood pressure (-24%), plasma triglycerides (-36%), hepatic triglycerides (-51%), and hepatic macrovesicular fat (-51%), but increased HIC (+23%), with a borderline increase in hepatic fibrosis. Bezafibrate reduced plasma triglycerides (-49%), hepatic triglycerides (-78%), hepatic macrovesicular fat (-90%), and blood pressure (-11%). We conclude that FED rats can be a suitable model for human NAFLD. Drugs administered to treat various aspects of the metabolic syndrome could have hepatic effects. An increase in HIC in rats with NAFLD could be associated with increased hepatic fibrosis.
Similar articles
- Effects of antihypertensive and triglyceride-lowering agents on hepatic copper concentrations in rats with fatty liver disease.
Ackerman Z, Skarzinski G, Grozovski M, Oron-Herman M, Sela BA. Ackerman Z, et al. Basic Clin Pharmacol Toxicol. 2014 Dec;115(6):545-51. doi: 10.1111/bcpt.12283. Epub 2014 Aug 6. Basic Clin Pharmacol Toxicol. 2014. PMID: 24975050 - Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver.
Ackerman Z, Grozovski M, Oron-Herman M, Rosenthal T, Sela BA, Amir G. Ackerman Z, et al. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):37-42. doi: 10.1111/bcpt.12067. Epub 2013 Apr 16. Basic Clin Pharmacol Toxicol. 2013. PMID: 23489555 - Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.
Ackerman Z, Oron-Herman M, Rosenthal T, Pappo O, Link G, Sela BA, Grozovski M. Ackerman Z, et al. Dig Dis Sci. 2008 Mar;53(3):777-84. doi: 10.1007/s10620-007-9911-4. Epub 2007 Aug 22. Dig Dis Sci. 2008. PMID: 17710547 - Risk reduction therapy for syndrome X: comparison of several treatments.
Oron-Herman M, Sela BA, Rosenthal T. Oron-Herman M, et al. Am J Hypertens. 2005 Mar;18(3):372-8. doi: 10.1016/j.amjhyper.2004.10.012. Am J Hypertens. 2005. PMID: 15797656 - Hepatic effects of rosiglitazone in rats with the metabolic syndrome.
Ackerman Z, Oron-Herman M, Pappo O, Peleg E, Safadi R, Schmilovitz-Weiss H, Grozovski M. Ackerman Z, et al. Basic Clin Pharmacol Toxicol. 2010 Aug;107(2):663-8. doi: 10.1111/j.1742-7843.2010.00553.x. Epub 2010 Mar 4. Basic Clin Pharmacol Toxicol. 2010. PMID: 20210788
Cited by
- Soybean Oil Is More Obesogenic and Diabetogenic than Coconut Oil and Fructose in Mouse: Potential Role for the Liver.
Deol P, Evans JR, Dhahbi J, Chellappa K, Han DS, Spindler S, Sladek FM. Deol P, et al. PLoS One. 2015 Jul 22;10(7):e0132672. doi: 10.1371/journal.pone.0132672. eCollection 2015. PLoS One. 2015. PMID: 26200659 Free PMC article. - Predicting the effects of a high-energy diet on fatty liver and hippocampal-dependent memory in male rats.
Darling JN, Ross AP, Bartness TJ, Parent MB. Darling JN, et al. Obesity (Silver Spring). 2013 May;21(5):910-7. doi: 10.1002/oby.20167. Obesity (Silver Spring). 2013. PMID: 23784893 Free PMC article. - Recent advances in the pathogenesis of hereditary fructose intolerance: implications for its treatment and the understanding of fructose-induced non-alcoholic fatty liver disease.
Buziau AM, Schalkwijk CG, Stehouwer CDA, Tolan DR, Brouwers MCGJ. Buziau AM, et al. Cell Mol Life Sci. 2020 May;77(9):1709-1719. doi: 10.1007/s00018-019-03348-2. Epub 2019 Nov 12. Cell Mol Life Sci. 2020. PMID: 31713637 Free PMC article. Review. - A high fructose diet impairs spatial memory in male rats.
Ross AP, Bartness TJ, Mielke JG, Parent MB. Ross AP, et al. Neurobiol Learn Mem. 2009 Oct;92(3):410-6. doi: 10.1016/j.nlm.2009.05.007. Epub 2009 Jun 12. Neurobiol Learn Mem. 2009. PMID: 19500683 Free PMC article. - CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH).
Najjar SM, Russo L. Najjar SM, et al. Semin Immunopathol. 2014 Jan;36(1):55-71. doi: 10.1007/s00281-013-0407-3. Epub 2013 Nov 21. Semin Immunopathol. 2014. PMID: 24258517 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources